Yoon Sun Park

Yoon Sun Park

Auto-generated profile, based on publicly available information

Yoon Sun Park

Wellmarkerbio Co., Ltd., Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
The development of first-generation immune-checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 ushered in a new era in anticancer therapy. Although immune-checkpoint blockade therapies have shown clinical success, a substantial number of patients yet fail to benefit. Many studies are under way to discover next-generation immunotherapeutic targets. Immunoglobulin superfamily member 1 (IGSF1) is a membrane glycoprotein proposed to regulate thyroid function. Despite containing 12 immunoglobin domains, a possible role for IGSF1, in immune response, remains unknown. Here, our studies revealed that IGSF1 is predominantly expressed in tumors but not normal tissues, and increased expression is observed in PD-L1low non–small cell lung cancer (NSCLC) cells as compared with PD-L1high cells. Subsequently, we developed and characterized an IGSF1-specific human monoclonal antibody, WM-A1, that effectively promoted antitumor immunity and overcame the limitations of first-generation immune-checkpoint inhibitors, likely via a distinct mechanism of action. We further demonstrated high WM-A1 efficacy in humanized peripheral blood mononuclear cells (PBMC), and syngeneic mouse models, finding additive efficacy in combination with an anti–PD-1 (a well-characterized checkpoint inhibitor). These findings support IGSF1 as an immune target that might complement existing cancer immunotherapeutics.

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Primers and RNAs used in the experiments.

17 June 2026
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Regulating of expression of Igsf1 is not critical for the proliferation, migration and invasion of cancer cells.

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
IGSF1 targeting antibody is developed and characterized by various methods

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
The combination efficacy of anti-PD-1 and WM-A1 in cancer-PBCM co-culture assay.

2 April 2024
Verified
Other
Open access
DKDong-In Koh
Dong-In Koh
MLMinki Lee
Minki Lee
YPYoon Sun Park
Yoon Sun Park
JSJae-Sik Shin
Jae-Sik Shin
JKJoseph Kim
Joseph Kim
DJDong-Hoon Jin
Dong-Hoon Jin
Primers and RNAs used in the experiments.